Analysts Set Expectations for ELEV Q2 Earnings

Elevation Oncology, Inc. (NASDAQ:ELEV) – Investment analysts at Leerink Partnrs issued their Q2 2025 EPS estimates for Elevation Oncology in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will post earnings per share of ($0.20) for the quarter. The consensus estimate for Elevation Oncology’s current full-year earnings is ($0.84) per share. Leerink Partnrs also issued estimates for Elevation Oncology’s FY2025 earnings at ($0.85) EPS, FY2026 earnings at ($0.88) EPS and FY2027 earnings at ($1.10) EPS.

Other equities research analysts also recently issued reports about the stock. Stephens reissued an “overweight” rating and set a $5.00 target price on shares of Elevation Oncology in a research report on Friday, December 6th. HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of Elevation Oncology in a report on Tuesday, January 14th. William Blair assumed coverage on Elevation Oncology in a research note on Friday, January 3rd. They issued an “outperform” rating for the company. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $7.00 target price on shares of Elevation Oncology in a research report on Thursday, December 19th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, Elevation Oncology currently has an average rating of “Buy” and an average target price of $7.20.

Elevation Oncology Stock Down 2.3 %

Shares of NASDAQ ELEV opened at $0.61 on Monday. The company has a quick ratio of 17.77, a current ratio of 17.77 and a debt-to-equity ratio of 0.45. The firm has a market cap of $35.99 million, a PE ratio of -0.74 and a beta of 1.31. The company’s fifty day simple moving average is $0.65 and its 200 day simple moving average is $0.72. Elevation Oncology has a 12-month low of $0.50 and a 12-month high of $5.83.

Institutional Trading of Elevation Oncology

Several hedge funds and other institutional investors have recently bought and sold shares of ELEV. SG Americas Securities LLC lifted its stake in shares of Elevation Oncology by 33.9% in the 4th quarter. SG Americas Securities LLC now owns 61,467 shares of the company’s stock worth $35,000 after purchasing an additional 15,560 shares during the period. JPMorgan Chase & Co. increased its holdings in Elevation Oncology by 175.9% during the third quarter. JPMorgan Chase & Co. now owns 61,334 shares of the company’s stock valued at $37,000 after buying an additional 39,101 shares during the last quarter. Palumbo Wealth Management LLC raised its position in Elevation Oncology by 294.5% in the fourth quarter. Palumbo Wealth Management LLC now owns 69,105 shares of the company’s stock worth $39,000 after acquiring an additional 51,590 shares during the period. Barclays PLC boosted its stake in shares of Elevation Oncology by 302.4% during the 3rd quarter. Barclays PLC now owns 72,077 shares of the company’s stock worth $43,000 after acquiring an additional 54,167 shares during the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of Elevation Oncology during the 4th quarter valued at $36,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.

About Elevation Oncology

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.